Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Pharmacological evaluation of clinically relevant concentrations of (2R,6R)-hydroxynorketamine.

Shaffer CL, Dutra JK, Tseng WC, Weber ML, Bogart LJ, Hales K, Pang J, Volfson D, Am Ende CW, Green ME, Buhl DL.

Neuropharmacology. 2019 Jul 15;153:73-81. doi: 10.1016/j.neuropharm.2019.04.019. Epub 2019 Apr 20.

PMID:
31015046
2.

Long live the worms: methods for maintaining and assessing the viability of intestinal stages of Parascaris spp. in vitro.

Scare JA, Steuer AE, Shaffer CL, Slusarewicz P, Mousley A, Nielsen MK.

Parasitology. 2018 Dec 18:1-9. doi: 10.1017/S0031182018002019. [Epub ahead of print]

PMID:
30561286
3.

Child and youth advocacy centres: A change in practice that can change a lifetime.

Shaffer CL, Smith TD, Ornstein AE.

Paediatr Child Health. 2018 Apr;23(2):116-118. doi: 10.1093/pch/pxy008. Epub 2018 Mar 1.

4.

In Vivo Structures of the Helicobacter pylori cag Type IV Secretion System.

Chang YW, Shaffer CL, Rettberg LA, Ghosal D, Jensen GJ.

Cell Rep. 2018 Apr 17;23(3):673-681. doi: 10.1016/j.celrep.2018.03.085.

5.

Prediction of Human Brain Penetration of P-glycoprotein and Breast Cancer Resistance Protein Substrates Using In Vitro Transporter Studies and Animal Models.

Feng B, Doran AC, Di L, West MA, Osgood SM, Mancuso JY, Shaffer CL, Tremaine L, Liras J.

J Pharm Sci. 2018 Aug;107(8):2225-2235. doi: 10.1016/j.xphs.2018.03.018. Epub 2018 Mar 30.

PMID:
29608887
6.

Discovery of Trifluoromethyl Glycol Carbamates as Potent and Selective Covalent Monoacylglycerol Lipase (MAGL) Inhibitors for Treatment of Neuroinflammation.

McAllister LA, Butler CR, Mente S, O'Neil SV, Fonseca KR, Piro JR, Cianfrogna JA, Foley TL, Gilbert AM, Harris AR, Helal CJ, Johnson DS, Montgomery JI, Nason DM, Noell S, Pandit J, Rogers BN, Samad TA, Shaffer CL, da Silva RG, Uccello DP, Webb D, Brodney MA.

J Med Chem. 2018 Apr 12;61(7):3008-3026. doi: 10.1021/acs.jmedchem.8b00070. Epub 2018 Mar 15.

PMID:
29498843
7.

Genetic signatures for Helicobacter pylori strains of West African origin.

Bullock KK, Shaffer CL, Brooks AW, Secka O, Forsyth MH, McClain MS, Cover TL.

PLoS One. 2017 Nov 29;12(11):e0188804. doi: 10.1371/journal.pone.0188804. eCollection 2017.

8.

Reverse and Forward Translational Neuropharmacology in Psychiatric Drug Discovery.

Shaffer CL.

Clin Pharmacol Ther. 2018 Feb;103(2):193-195. doi: 10.1002/cpt.901. Epub 2017 Oct 27.

PMID:
29076553
9.

Discovery and Characterization of (R)-6-Neopentyl-2-(pyridin-2-ylmethoxy)-6,7-dihydropyrimido[2,1-c][1,4]oxazin-4(9H)-one (PF-06462894), an Alkyne-Lacking Metabotropic Glutamate Receptor 5 Negative Allosteric Modulator Profiled in both Rat and Nonhuman Primates.

Stepan AF, Claffey MM, Reese MR, Balan G, Barreiro G, Barricklow J, Bohanon MJ, Boscoe BP, Cappon GD, Chenard LK, Cianfrogna J, Chen L, Coffman KJ, Drozda SE, Dunetz JR, Ghosh S, Hou X, Houle C, Karki K, Lazzaro JT, Mancuso JY, Marcek JM, Miller EL, Moen MA, O'Neil S, Sakurada I, Skaddan M, Parikh V, Smith DL, Trapa P, Tuttle JB, Verhoest PR, Walker DP, Won A, Wright AS, Whritenour J, Zasadny K, Zaleska MM, Zhang L, Shaffer CL.

J Med Chem. 2017 Sep 28;60(18):7764-7780. doi: 10.1021/acs.jmedchem.7b00604. Epub 2017 Sep 13.

PMID:
28817277
10.

Mechanisms of Skin Toxicity Associated with Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators.

Shah F, Stepan AF, O'Mahony A, Velichko S, Folias AE, Houle C, Shaffer CL, Marcek J, Whritenour J, Stanton R, Berg EL.

Cell Chem Biol. 2017 Jul 20;24(7):858-869.e5. doi: 10.1016/j.chembiol.2017.06.003. Epub 2017 Jun 29.

11.

Insights from mathematical modeling for convection-enhanced intraputamenal delivery of GDNF.

Belova E, Shaffer CL, Trapa PE.

Med Biol Eng Comput. 2017 Dec;55(12):2069-2077. doi: 10.1007/s11517-017-1650-x. Epub 2017 May 11.

12.

Student Preparation for PGY1 Residency Training by US Colleges of Pharmacy: Survey of the Residency Program Director Perspective.

Mutz AB, Beyer J, Dickson WL, Gutman I, Yucebay F, Lepkowsky M, Chan J, Carter K, Shaffer CL, Fuller PD.

Hosp Pharm. 2017 Feb;52(2):117-123. doi: 10.1310/hpj5202-117.

13.

Attenuation of ketamine-induced impairment in verbal learning and memory in healthy volunteers by the AMPA receptor potentiator PF-04958242.

Ranganathan M, DeMartinis N, Huguenel B, Gaudreault F, Bednar MM, Shaffer CL, Gupta S, Cahill J, Sherif MA, Mancuso J, Zumpano L, D'Souza DC.

Mol Psychiatry. 2017 Nov;22(11):1633-1640. doi: 10.1038/mp.2017.6. Epub 2017 Feb 28.

PMID:
28242871
14.

Purine Biosynthesis Metabolically Constrains Intracellular Survival of Uropathogenic Escherichia coli.

Shaffer CL, Zhang EW, Dudley AG, Dixon BREA, Guckes KR, Breland EJ, Floyd KA, Casella DP, Algood HMS, Clayton DB, Hadjifrangiskou M.

Infect Immun. 2016 Dec 29;85(1). pii: e00471-16. doi: 10.1128/IAI.00471-16. Print 2017 Jan.

15.

Quantitative projection of human brain penetration of the H3 antagonist PF-03654746 by integrating rat-derived brain partitioning and PET receptor occupancy.

Sawant-Basak A, Chen L, Shaffer CL, Palumbo D, Schmidt A, Tseng E, Spracklin DK, Gallezot JD, Labaree D, Nabulsi N, Huang Y, Carson RE, McCarthy T.

Xenobiotica. 2017 Feb;47(2):119-126. doi: 10.3109/00498254.2016.1166531. Epub 2016 Jun 29.

PMID:
27353353
16.

Pathogenic Helicobacter pylori strains translocate DNA and activate TLR9 via the cancer-associated cag type IV secretion system.

Varga MG, Shaffer CL, Sierra JC, Suarez G, Piazuelo MB, Whitaker ME, Romero-Gallo J, Krishna US, Delgado A, Gomez MA, Good JA, Almqvist F, Skaar EP, Correa P, Wilson KT, Hadjifrangiskou M, Peek RM.

Oncogene. 2016 Dec 1;35(48):6262-6269. doi: 10.1038/onc.2016.158. Epub 2016 May 9.

17.

Peptidomimetic Small Molecules Disrupt Type IV Secretion System Activity in Diverse Bacterial Pathogens.

Shaffer CL, Good JA, Kumar S, Krishnan KS, Gaddy JA, Loh JT, Chappell J, Almqvist F, Cover TL, Hadjifrangiskou M.

MBio. 2016 Apr 26;7(2):e00221-16. doi: 10.1128/mBio.00221-16.

18.

Drug-induced Skin Lesions in Cynomolgus Macaques Treated with Metabotropic Glutamate Receptor 5 (mGluR5) Negative Allosteric Modulators.

Palanisamy GS, Marcek JM, Cappon GD, Whritenour J, Shaffer CL, Brady JT, Houle C.

Toxicol Pathol. 2015 Oct;43(7):995-1003. doi: 10.1177/0192623315588114. Epub 2015 Jun 9.

PMID:
26059827
19.

PDE5 inhibition improves acquisition processes after learning via a central mechanism.

Akkerman S, Blokland A, van Goethem NP, Cremers P, Shaffer CL, Osgood SM, Steinbusch HW, Prickaerts J.

Neuropharmacology. 2015 Oct;97:233-9. doi: 10.1016/j.neuropharm.2015.04.019. Epub 2015 May 29.

PMID:
26027948
20.

The discovery and characterization of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor potentiator N-{(3S,4S)-4-[4-(5-cyano-2-thienyl)phenoxy]tetrahydrofuran-3-yl}propane-2-sulfonamide (PF-04958242).

Shaffer CL, Patel NC, Schwarz J, Scialis RJ, Wei Y, Hou XJ, Xie L, Karki K, Bryce DK, Osgood SM, Hoffmann WE, Lazzaro JT, Chang C, McGinnis DF, Lotarski SM, Liu J, Obach RS, Weber ML, Chen L, Zasadny KR, Seymour PA, Schmidt CJ, Hajós M, Hurst RS, Pandit J, O'Donnell CJ.

J Med Chem. 2015 May 28;58(10):4291-308. doi: 10.1021/acs.jmedchem.5b00300. Epub 2015 May 14.

PMID:
25905800
21.
22.

Adhesive fiber stratification in uropathogenic Escherichia coli biofilms unveils oxygen-mediated control of type 1 pili.

Floyd KA, Moore JL, Eberly AR, Good JA, Shaffer CL, Zaver H, Almqvist F, Skaar EP, Caprioli RM, Hadjifrangiskou M.

PLoS Pathog. 2015 Mar 4;11(3):e1004697. doi: 10.1371/journal.ppat.1004697. eCollection 2015 Mar.

23.

Pilicide ec240 disrupts virulence circuits in uropathogenic Escherichia coli.

Greene SE, Pinkner JS, Chorell E, Dodson KW, Shaffer CL, Conover MS, Livny J, Hadjifrangiskou M, Almqvist F, Hultgren SJ.

MBio. 2014 Oct 28;5(6):e02038. doi: 10.1128/mBio.02038-14.

24.

Enhancing ketamine translational pharmacology via receptor occupancy normalization.

Shaffer CL, Osgood SM, Smith DL, Liu J, Trapa PE.

Neuropharmacology. 2014 Nov;86:174-80. doi: 10.1016/j.neuropharm.2014.07.008. Epub 2014 Jul 22.

PMID:
25063581
25.

Diphenhydramine has similar interspecies net active influx at the blood-brain barrier.

Shaffer CL, Osgood SM, Mancuso JY, Doran AC.

J Pharm Sci. 2014 May;103(5):1557-62. doi: 10.1002/jps.23927. Epub 2014 Mar 13.

PMID:
24633923
26.

Phosphodiesterase 10A inhibitor MP-10 effects in primates: comparison with risperidone and mechanistic implications.

Uthayathas S, Masilamoni GJ, Shaffer CL, Schmidt CJ, Menniti FS, Papa SM.

Neuropharmacology. 2014 Feb;77:257-67.

27.

Human and Helicobacter pylori coevolution shapes the risk of gastric disease.

Kodaman N, Pazos A, Schneider BG, Piazuelo MB, Mera R, Sobota RS, Sicinschi LA, Shaffer CL, Romero-Gallo J, de Sablet T, Harder RH, Bravo LE, Peek RM Jr, Wilson KT, Cover TL, Williams SM, Correa P.

Proc Natl Acad Sci U S A. 2014 Jan 28;111(4):1455-60. doi: 10.1073/pnas.1318093111. Epub 2014 Jan 13.

28.

Discovery and preclinical characterization of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo-[3,4-b]pyrazine (PF470): a highly potent, selective, and efficacious metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator.

Zhang L, Balan G, Barreiro G, Boscoe BP, Chenard LK, Cianfrogna J, Claffey MM, Chen L, Coffman KJ, Drozda SE, Dunetz JR, Fonseca KR, Galatsis P, Grimwood S, Lazzaro JT, Mancuso JY, Miller EL, Reese MR, Rogers BN, Sakurada I, Skaddan M, Smith DL, Stepan AF, Trapa P, Tuttle JB, Verhoest PR, Walker DP, Wright AS, Zaleska MM, Zasadny K, Shaffer CL.

J Med Chem. 2014 Feb 13;57(3):861-77. doi: 10.1021/jm401622k. Epub 2014 Jan 22.

PMID:
24392688
29.

Discovery and characterization of a novel dihydroisoxazole class of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor potentiators.

Patel NC, Schwarz J, Hou XJ, Hoover DJ, Xie L, Fliri AJ, Gallaschun RJ, Lazzaro JT, Bryce DK, Hoffmann WE, Hanks AN, McGinnis D, Marr ES, Gazard JL, Hajós M, Scialis RJ, Hurst RS, Shaffer CL, Pandit J, O'Donnell CJ.

J Med Chem. 2013 Nov 27;56(22):9180-91. doi: 10.1021/jm401274b. Epub 2013 Nov 11.

PMID:
24215237
30.

The effect of ketamine-contaminated control plasma on small-molecule plasma protein binding.

Osgood SM, Liu J, Shaffer CL.

Bioanalysis. 2013 Nov;5(21):2607-12. doi: 10.4155/bio.13.230.

PMID:
24180502
31.

Strong cross-system interactions drive the activation of the QseB response regulator in the absence of its cognate sensor.

Guckes KR, Kostakioti M, Breland EJ, Gu AP, Shaffer CL, Martinez CR 3rd, Hultgren SJ, Hadjifrangiskou M.

Proc Natl Acad Sci U S A. 2013 Oct 8;110(41):16592-7. doi: 10.1073/pnas.1315320110. Epub 2013 Sep 23.

32.

Positive allosteric modulation of AMPA receptors from efficacy to toxicity: the interspecies exposure-response continuum of the novel potentiator PF-4778574.

Shaffer CL, Hurst RS, Scialis RJ, Osgood SM, Bryce DK, Hoffmann WE, Lazzaro JT, Hanks AN, Lotarski S, Weber ML, Liu J, Menniti FS, Schmidt CJ, Hajós M.

J Pharmacol Exp Ther. 2013 Oct;347(1):212-24. doi: 10.1124/jpet.113.204735. Epub 2013 Jul 30.

PMID:
23899905
33.

Neurophysiological signals as potential translatable biomarkers for modulation of metabotropic glutamate 5 receptors.

Harvey BD, Siok CJ, Kiss T, Volfson D, Grimwood S, Shaffer CL, Hajós M.

Neuropharmacology. 2013 Dec;75:19-30. doi: 10.1016/j.neuropharm.2013.06.020. Epub 2013 Jul 4.

PMID:
23831682
34.

Therapeutic doses of antidepressants are projected not to inhibit human α4β2 nicotinic acetylcholine receptors.

Weber ML, Hofland CM, Shaffer CL, Flik G, Cremers T, Hurst RS, Rollema H.

Neuropharmacology. 2013 Sep;72:88-95. doi: 10.1016/j.neuropharm.2013.04.027. Epub 2013 Apr 30.

PMID:
23639435
35.

Assessment of adverse effects of neurotropic drugs in monkeys with the "drug effects on the nervous system" (DENS) scale.

Uthayathas S, Shaffer CL, Menniti FS, Schmidt CJ, Papa SM.

J Neurosci Methods. 2013 Apr 30;215(1):97-102. doi: 10.1016/j.jneumeth.2013.02.004. Epub 2013 Feb 16.

36.

Rhythmic theta and delta activity of cortical and hippocampal neuronal networks in genetically or pharmacologically induced N-methyl-D-aspartate receptor hypofunction under urethane anesthesia.

Kiss T, Feng J, Hoffmann WE, Shaffer CL, Hajós M.

Neuroscience. 2013 May 1;237:255-67. doi: 10.1016/j.neuroscience.2013.01.058. Epub 2013 Feb 8.

PMID:
23396086
37.

Comparative genomic analysis of East Asian and non-Asian Helicobacter pylori strains identifies rapidly evolving genes.

Duncan SS, Valk PL, McClain MS, Shaffer CL, Metcalf JA, Bordenstein SR, Cover TL.

PLoS One. 2013;8(1):e55120. doi: 10.1371/journal.pone.0055120. Epub 2013 Jan 31.

38.

Downregulated Th17 responses are associated with reduced gastritis in Helicobacter pylori-infected children.

Serrano C, Wright SW, Bimczok D, Shaffer CL, Cover TL, Venegas A, Salazar MG, Smythies LE, Harris PR, Smith PD.

Mucosal Immunol. 2013 Sep;6(5):950-959. doi: 10.1038/mi.2012.133. Epub 2013 Jan 9.

39.

An evaluation of using rat-derived single-dose neuropharmacokinetic parameters to project accurately large animal unbound brain drug concentrations.

Doran AC, Osgood SM, Mancuso JY, Shaffer CL.

Drug Metab Dispos. 2012 Nov;40(11):2162-73. doi: 10.1124/dmd.112.046391. Epub 2012 Aug 16.

PMID:
22899853
40.

Phosphodiesterase type 5 (PDE5) inhibition improves object recognition memory: indications for central and peripheral mechanisms.

Reneerkens OA, Rutten K, Akkerman S, Blokland A, Shaffer CL, Menniti FS, Steinbusch HW, Prickaerts J.

Neurobiol Learn Mem. 2012 May;97(4):370-9. doi: 10.1016/j.nlm.2012.02.008. Epub 2012 Mar 8.

PMID:
22426465
41.

J-Western forms of Helicobacter pylori cagA constitute a distinct phylogenetic group with a widespread geographic distribution.

Duncan SS, Valk PL, Shaffer CL, Bordenstein SR, Cover TL.

J Bacteriol. 2012 Mar;194(6):1593-604. doi: 10.1128/JB.06340-11. Epub 2012 Jan 13.

42.

Using Simcyp to project human oral pharmacokinetic variability in early drug research to mitigate mechanism-based adverse events.

Shaffer CL, Scialis RJ, Rong H, Obach RS.

Biopharm Drug Dispos. 2012 Mar;33(2):72-84. doi: 10.1002/bdd.1768. Epub 2012 Jan 17.

PMID:
22213407
43.

Helicobacter pylori exploits a unique repertoire of type IV secretion system components for pilus assembly at the bacteria-host cell interface.

Shaffer CL, Gaddy JA, Loh JT, Johnson EM, Hill S, Hennig EE, McClain MS, McDonald WH, Cover TL.

PLoS Pathog. 2011 Sep;7(9):e1002237. doi: 10.1371/journal.ppat.1002237. Epub 2011 Sep 1.

44.

Analysis of cagA in Helicobacter pylori strains from Colombian populations with contrasting gastric cancer risk reveals a biomarker for disease severity.

Loh JT, Shaffer CL, Piazuelo MB, Bravo LE, McClain MS, Correa P, Cover TL.

Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2237-49. doi: 10.1158/1055-9965.EPI-11-0548. Epub 2011 Aug 22.

45.

Strategies to optimize the brain availability of central nervous system drug candidates.

Wager TT, Villalobos A, Verhoest PR, Hou X, Shaffer CL.

Expert Opin Drug Discov. 2011 Apr;6(4):371-81. doi: 10.1517/17460441.2011.564158. Epub 2011 Mar 22.

PMID:
22646015
46.

Phylogeographic origin of Helicobacter pylori is a determinant of gastric cancer risk.

de Sablet T, Piazuelo MB, Shaffer CL, Schneider BG, Asim M, Chaturvedi R, Bravo LE, Sicinschi LA, Delgado AG, Mera RM, Israel DA, Romero-Gallo J, Peek RM Jr, Cover TL, Correa P, Wilson KT.

Gut. 2011 Sep;60(9):1189-95. doi: 10.1136/gut.2010.234468. Epub 2011 Feb 25.

47.

Partial agonists of the α3β4* neuronal nicotinic acetylcholine receptor reduce ethanol consumption and seeking in rats.

Chatterjee S, Steensland P, Simms JA, Holgate J, Coe JW, Hurst RS, Shaffer CL, Lowe J, Rollema H, Bartlett SE.

Neuropsychopharmacology. 2011 Feb;36(3):603-15. doi: 10.1038/npp.2010.191. Epub 2010 Nov 3.

48.

Molecular evolution of the Helicobacter pylori vacuolating toxin gene vacA.

Gangwer KA, Shaffer CL, Suerbaum S, Lacy DB, Cover TL, Bordenstein SR.

J Bacteriol. 2010 Dec;192(23):6126-35. doi: 10.1128/JB.01081-10. Epub 2010 Sep 24.

49.

A novel series of [3.2.1] azabicyclic biaryl ethers as alpha3beta4 and alpha6/4beta4 nicotinic receptor agonists.

Lowe JA 3rd, DeNinno SL, Coe JW, Zhang L, Mente S, Hurst RS, Mather RJ, Ward KM, Shrikhande A, Rollema H, Johnson DE, Horner W, Gorczyca R, Tingley FD 3rd, Kozak R, Majchrzak MJ, Tritto T, Sadlier J, Shaffer CL, Ellerbrock B, Osgood SM, MacDougall MC, McDowell LL.

Bioorg Med Chem Lett. 2010 Aug 15;20(16):4749-52. doi: 10.1016/j.bmcl.2010.06.142.

PMID:
20663668
50.

Prevention of ketamine-induced working memory impairments by AMPA potentiators in a nonhuman primate model of cognitive dysfunction.

Roberts BM, Holden DE, Shaffer CL, Seymour PA, Menniti FS, Schmidt CJ, Williams GV, Castner SA.

Behav Brain Res. 2010 Sep 1;212(1):41-8. doi: 10.1016/j.bbr.2010.03.039. Epub 2010 Mar 27.

PMID:
20347881

Supplemental Content

Loading ...
Support Center